TY - JOUR AU - Chatenoud, L. AU - Ferran, C. AU - Reuter, A. AU - Legendre, C. AU - Gevaert, Y. AU - Kreis, H. PY - 1989 DA - 1989// TI - Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected] JO - N Engl J Med VL - 320 UR - https://doi.org/10.1056/NEJM198905253202117 DO - 10.1056/NEJM198905253202117 ID - Chatenoud1989 ER - TY - JOUR AU - Chatenoud, L. AU - Ferran, C. AU - Legendre, C. AU - Thouard, I. AU - Merite, S. AU - Reuter, A. PY - 1990 DA - 1990// TI - In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids JO - Transplantation VL - 49 UR - https://doi.org/10.1097/00007890-199004000-00009 DO - 10.1097/00007890-199004000-00009 ID - Chatenoud1990 ER - TY - JOUR AU - Pihusch, R. AU - Holler, E. AU - Mühlbayer, D. AU - Göhring, P. AU - Stötzer, O. AU - Pihusch, M. PY - 2002 DA - 2002// TI - The impact of antithymocyte globulin on short-term toxicity after allogeneic stem cell transplantation JO - Bone Marrow Transplant VL - 30 UR - https://doi.org/10.1038/sj.bmt.1703640 DO - 10.1038/sj.bmt.1703640 ID - Pihusch2002 ER - TY - JOUR AU - Suntharalingam, G. AU - Perry, M. R. AU - Ward, S. AU - Brett, S. J. AU - Castello-Cortes, A. AU - Brunner, M. D. PY - 2006 DA - 2006// TI - Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN 1412 JO - N Engl J Med VL - 355 UR - https://doi.org/10.1056/NEJMoa063842 DO - 10.1056/NEJMoa063842 ID - Suntharalingam2006 ER - TY - STD TI - Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94 ID - ref5 ER - TY - STD TI - Freeman CL, Morschhauser F, Sehn L, Dixon M, Houghton R, Lamy T, et al. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood. 2015;126 ID - ref6 ER - TY - JOUR AU - Wing, M. G. AU - Moreau, T. AU - Greenwood, J. AU - Smith, R. M. AU - Hale, G. AU - Isaacs, J. PY - 1996 DA - 1996// TI - Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells JO - J Clin Invest VL - 98 UR - https://doi.org/10.1172/JCI119110 DO - 10.1172/JCI119110 ID - Wing1996 ER - TY - JOUR AU - Alig, S. K. AU - Dreyling, M. AU - Seppi, B. AU - Aulinger, B. AU - Witkowski, L. AU - Rieger, C. T. PY - 2015 DA - 2015// TI - Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature JO - Eur J Haematol VL - 94 UR - https://doi.org/10.1111/ejh.12396 DO - 10.1111/ejh.12396 ID - Alig2015 ER - TY - JOUR AU - de Vos, S. AU - Forero-Torres, A. AU - Ansell, S. M. AU - Kahl, B. AU - Cheson, B. D. AU - Bartlett, N. L. PY - 2014 DA - 2014// TI - A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors JO - J Hematol Oncol VL - 7 UR - https://doi.org/10.1186/1756-8722-7-44 DO - 10.1186/1756-8722-7-44 ID - de Vos2014 ER - TY - STD TI - Rotz SJ, Leino D, Szabo S, Mangino JL, Turpin BK, Pressey JG. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatr Blood Cancer. 2017;64:e26642. ID - ref10 ER - TY - JOUR AU - Tonini, G. AU - Santini, D. AU - Vincenzi, B. AU - Borzomati, D. AU - Dicuonzo, G. AU - La Cesa, A. PY - 2002 DA - 2002// TI - Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients JO - J Biol Regul Homeost Agents VL - 16 ID - Tonini2002 ER - TY - JOUR AU - Aue, G. AU - Njuguna, N. AU - Tian, X. AU - Soto, S. AU - Hughes, T. AU - Vire, B. PY - 2009 DA - 2009// TI - Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia JO - Haematologica VL - 94 UR - https://doi.org/10.3324/haematol.2009.005835 DO - 10.3324/haematol.2009.005835 ID - Aue2009 ER - TY - JOUR AU - Abboud, R. AU - Keller, J. AU - Slade, M. AU - DiPersio, J. F. AU - Westervelt, P. AU - Rettig, M. P. PY - 2016 DA - 2016// TI - Severe cytokine-release syndrome after T cell–replete peripheral blood Haploidentical donor transplantation is associated with poor survival and anti–IL-6 therapy is safe and well tolerated JO - Biol Blood Marrow Transplant VL - 22 UR - https://doi.org/10.1016/j.bbmt.2016.06.010 DO - 10.1016/j.bbmt.2016.06.010 ID - Abboud2016 ER - TY - JOUR AU - Cho, C. AU - Perales, M. A. PY - 2016 DA - 2016// TI - Rapid identification of cytokine release syndrome after haploidentical PBSC transplantation and successful therapy with tocilizumab JO - Bone Marrow Transplant VL - 51 UR - https://doi.org/10.1038/bmt.2016.229 DO - 10.1038/bmt.2016.229 ID - Cho2016 ER - TY - JOUR AU - Tisoncik, J. R. AU - Korth, M. J. AU - Simmons, C. P. AU - Farrar, J. AU - Martin, T. R. AU - Katze, M. G. PY - 2012 DA - 2012// TI - Into the eye of the cytokine storm JO - Microbiol Mol Biol Rev VL - 76 UR - https://doi.org/10.1128/MMBR.05015-11 DO - 10.1128/MMBR.05015-11 ID - Tisoncik2012 ER - TY - JOUR AU - de Jong, M. D. AU - Simmons, C. P. AU - Thanh, T. T. AU - Hien, V. M. AU - Smith, G. J. D. AU - Chau, T. N. B. PY - 2006 DA - 2006// TI - Fatal outcome of human influenza a (H5N1) is associated with high viral load and hypercytokinemia JO - Nat Med VL - 12 UR - https://doi.org/10.1038/nm1477 DO - 10.1038/nm1477 ID - de Jong2006 ER - TY - JOUR AU - Przepiorka, D. AU - Ko, C. -. W. AU - Deisseroth, A. AU - Yancey, C. L. AU - Candau-Chacon, R. AU - Chiu, H. -. J. PY - 2015 DA - 2015// TI - FDA Approval: Blinatumomab JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-15-0612 DO - 10.1158/1078-0432.CCR-15-0612 ID - Przepiorka2015 ER - TY - STD TI - Rose S. First-Ever CAR T-cell Therapy Approved in U.S. Cancer Discov. 2017;7(10):OF1. https://doi.org/10.1158/2159-8290.CD-NB2017-126. ID - ref18 ER - TY - STD TI - Roberts ZJ, Better M, Bot A, Roberts MR, Ribas A. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL. Leuk Lymphoma. 2017:1-12. ID - ref19 ER - TY - JOUR AU - Sharpe, M. AU - Mount, N. PY - 2015 DA - 2015// TI - Genetically modified T cells in cancer therapy: opportunities and challenges JO - Dis Model Mech VL - 8 UR - https://doi.org/10.1242/dmm.018036 DO - 10.1242/dmm.018036 ID - Sharpe2015 ER - TY - STD TI - Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the “high-hanging fruit”. Nat Rev Drug Discov. 2017; ID - ref21 ER - TY - JOUR AU - Teachey, D. T. AU - Rheingold, S. R. AU - Maude, S. L. AU - Zugmaier, G. AU - Barrett, D. M. AU - Seif, A. E. PY - 2013 DA - 2013// TI - Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy JO - Blood VL - 121 UR - https://doi.org/10.1182/blood-2013-02-485623 DO - 10.1182/blood-2013-02-485623 ID - Teachey2013 ER - TY - JOUR AU - Morgan, R. A. AU - Yang, J. C. AU - Kitano, M. AU - Dudley, M. E. AU - Laurencot, C. M. AU - Rosenberg, S. A. PY - 2010 DA - 2010// TI - Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 JO - Mol Ther VL - 18 UR - https://doi.org/10.1038/mt.2010.24 DO - 10.1038/mt.2010.24 ID - Morgan2010 ER - TY - STD TI - Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321-30. ID - ref24 ER - TY - JOUR AU - Porter, D. L. AU - Levine, B. L. AU - Kalos, M. AU - Bagg, A. AU - June, C. H. PY - 2011 DA - 2011// TI - Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia JO - N Engl J Med VL - 365 UR - https://doi.org/10.1056/NEJMoa1103849 DO - 10.1056/NEJMoa1103849 ID - Porter2011 ER - TY - STD TI - Hay KA, Hanafi L-A, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T cell therapy. Blood. 2017; ID - ref26 ER - TY - JOUR AU - Kantarjian, H. AU - Stein, A. AU - Gökbuget, N. AU - Fielding, A. K. AU - Schuh, A. C. AU - Ribera, J. -. M. PY - 2017 DA - 2017// TI - Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMoa1609783 DO - 10.1056/NEJMoa1609783 ID - Kantarjian2017 ER - TY - JOUR AU - Neelapu, S. S. AU - Tummala, S. AU - Kebriaei, P. AU - Wierda, W. AU - Gutierrez, C. AU - Locke, F. L. PY - 2018 DA - 2018// TI - Chimeric antigen receptor T-cell therapy - assessment and management of toxicities JO - Nat Rev Clin Oncol VL - 15 UR - https://doi.org/10.1038/nrclinonc.2017.148 DO - 10.1038/nrclinonc.2017.148 ID - Neelapu2018 ER - TY - JOUR AU - Lee, D. W. AU - Gardner, R. AU - Porter, D. L. AU - Louis, C. U. AU - Ahmed, N. AU - Jensen, M. PY - 2014 DA - 2014// TI - Current concepts in the diagnosis and management of cytokine release syndrome JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-05-552729 DO - 10.1182/blood-2014-05-552729 ID - Lee2014 ER - TY - JOUR AU - Klinger, M. AU - Brandl, C. AU - Zugmaier, G. AU - Hijazi, Y. AU - Bargou, R. C. AU - Topp, M. S. PY - 2012 DA - 2012// TI - Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2012-01-400515 DO - 10.1182/blood-2012-01-400515 ID - Klinger2012 ER - TY - JOUR AU - Brudno, J. N. AU - Kochenderfer, J. N. AU - Eshhar, Z. AU - Waks, T. AU - Gross, G. AU - Schindler, D. PY - 2016 DA - 2016// TI - Toxicities of chimeric antigen receptor T cells: recognition and management JO - Blood VL - 127 UR - https://doi.org/10.1182/blood-2016-04-703751 DO - 10.1182/blood-2016-04-703751 ID - Brudno2016 ER - TY - JOUR AU - Maude, S. L. AU - Teachey, D. T. AU - Porter, D. L. AU - Grupp, S. A. PY - 2015 DA - 2015// TI - CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia JO - Blood VL - 125 UR - https://doi.org/10.1182/blood-2014-12-580068 DO - 10.1182/blood-2014-12-580068 ID - Maude2015 ER - TY - STD TI - Hu Y, Wu Z, Luo Y, Shi J, Yu J, Pu C, Liang Z, Wei G, Cui Q, Sun J, Jiang J, Xie J, Tan Y, Ni W, Tu J, Wang J, Jin A, Zhang H, Cai Z, Xiao L, Huang H. Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia. Clin Cancer Res. 2017;23(13):3297-306. ID - ref33 ER - TY - JOUR AU - Brentjens, R. J. AU - Davila, M. L. AU - Riviere, I. AU - Park, J. AU - Wang, X. AU - Cowell, L. G. PY - 2013 DA - 2013// TI - CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia JO - Sci Transl Med VL - 5 UR - https://doi.org/10.1126/scitranslmed.3005930 DO - 10.1126/scitranslmed.3005930 ID - Brentjens2013 ER - TY - JOUR AU - Turtle, C. J. AU - Hanafi, L. AU - Berger, C. AU - Gooley, T. A. AU - Cherian, S. AU - Hudecek, M. PY - 2016 DA - 2016// TI - CD19 CAR – T cells of defined CD4 + : CD8 + composition in adult B cell ALL patients JO - J Clin Invest VL - 1 ID - Turtle2016 ER - TY - JOUR AU - Davila, M. L. AU - Riviere, I. AU - Wang, X. AU - Bartido, S. AU - Park, J. AU - Curran, K. PY - 2014 DA - 2014// TI - Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia JO - Sci Transl Med VL - 6 UR - https://doi.org/10.1126/scitranslmed.3008226 DO - 10.1126/scitranslmed.3008226 ID - Davila2014 ER - TY - STD TI - Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, et al. The addition of the BTK inhibitor Ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma. Clin Cancer Res. 2016; ID - ref37 ER - TY - JOUR AU - Ruella, M. AU - Kenderian, S. S. AU - Shestova, O. AU - Klichinsky, M. AU - Melenhorst, J. J. AU - Wasik, M. A. PY - 2017 DA - 2017// TI - Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms JO - Leukemia VL - 31 UR - https://doi.org/10.1038/leu.2016.262 DO - 10.1038/leu.2016.262 ID - Ruella2017 ER - TY - JOUR AU - Lee, D. W. AU - Kochenderfer, J. N. AU - Stetler-Stevenson, M. AU - Cui, Y. K. AU - Delbrook, C. AU - Feldman, S. A. PY - 2015 DA - 2015// TI - T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial JO - Lancet VL - 385 UR - https://doi.org/10.1016/S0140-6736(14)61403-3 DO - 10.1016/S0140-6736(14)61403-3 ID - Lee2015 ER - TY - JOUR AU - Kalos, M. AU - Levine, B. L. AU - Porter, D. L. AU - Katz, S. AU - Grupp, S. A. AU - Bagg, A. PY - 2011 DA - 2011// TI - T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia JO - Sci Transl Med VL - 3 UR - https://doi.org/10.1126/scitranslmed.3002842 DO - 10.1126/scitranslmed.3002842 ID - Kalos2011 ER - TY - JOUR AU - Maude, S. L. AU - Frey, N. AU - Shaw, P. A. AU - Aplenc, R. AU - Barrett, D. M. AU - Bunin, N. J. PY - 2014 DA - 2014// TI - Chimeric antigen receptor T cells for sustained remissions in leukemia JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1407222 DO - 10.1056/NEJMoa1407222 ID - Maude2014 ER - TY - JOUR AU - Savoldo, B. AU - Ramos, C. A. AU - Liu, E. AU - Mims, M. P. AU - Keating, M. J. AU - Carrum, G. PY - 2011 DA - 2011// TI - CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients JO - J Clin Invest VL - 121 UR - https://doi.org/10.1172/JCI46110 DO - 10.1172/JCI46110 ID - Savoldo2011 ER - TY - JOUR AU - van der Stegen, S. J. C. AU - Hamieh, M. AU - Sadelain, M. PY - 2015 DA - 2015// TI - The pharmacology of second-generation chimeric antigen receptors JO - Nat Rev Drug Discov VL - 14 UR - https://doi.org/10.1038/nrd4597 DO - 10.1038/nrd4597 ID - van der Stegen2015 ER - TY - JOUR AU - Neelapu, S. S. AU - Locke, F. L. AU - Bartlett, N. L. AU - Lekakis, L. J. AU - Miklos, D. B. AU - Jacobson, C. A. PY - 2017 DA - 2017// TI - Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1707447 DO - 10.1056/NEJMoa1707447 ID - Neelapu2017 ER - TY - JOUR AU - Schuster, R. A. AU - Hong, S. Y. AU - Arnold, R. M. AU - White, D. B. PY - 2014 DA - 2014// TI - Investigating conflict in ICUs-is the clinicians’ perspective enough? JO - Crit Care Med VL - 42 UR - https://doi.org/10.1097/CCM.0b013e3182a27598 DO - 10.1097/CCM.0b013e3182a27598 ID - Schuster2014 ER - TY - JOUR AU - Howard, S. C. AU - Jones, D. P. AU - Pui, C. -. H. PY - 2011 DA - 2011// TI - The tumor lysis syndrome JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMra0904569 DO - 10.1056/NEJMra0904569 ID - Howard2011 ER - TY - JOUR AU - Singer, M. AU - Deutschman, C. S. AU - Seymour, C. W. AU - Shankar-Hari, M. AU - Annane, D. AU - Bauer, M. PY - 2016 DA - 2016// TI - The third international consensus definitions for Sepsis and septic shock (Sepsis-3) JO - JAMA VL - 315 UR - https://doi.org/10.1001/jama.2016.0287 DO - 10.1001/jama.2016.0287 ID - Singer2016 ER - TY - STD TI - Hill JA, Li D, Hay KA, Green ML, Cherian S, Chen X, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy. Blood. 2017; ID - ref48 ER - TY - JOUR AU - Brentjens, R. AU - Yeh, R. AU - Bernal, Y. AU - Riviere, I. AU - Sadelain, M. PY - 2010 DA - 2010// TI - Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial JO - Mol Ther VL - 18 UR - https://doi.org/10.1038/mt.2010.31 DO - 10.1038/mt.2010.31 ID - Brentjens2010 ER - TY - JOUR AU - Lenz, H. -. J. PY - 2007 DA - 2007// TI - Management and preparedness for infusion and hypersensitivity reactions JO - Oncologist VL - 12 UR - https://doi.org/10.1634/theoncologist.12-5-601 DO - 10.1634/theoncologist.12-5-601 ID - Lenz2007 ER - TY - JOUR AU - Demoly, P. AU - Adkinson, N. F. AU - Brockow, K. AU - Castells, M. AU - Chiriac, A. M. AU - Greenberger, P. A. PY - 2014 DA - 2014// TI - International consensus on drug allergy JO - Allergy VL - 69 UR - https://doi.org/10.1111/all.12350 DO - 10.1111/all.12350 ID - Demoly2014 ER - TY - JOUR AU - Maus, M. V. AU - Haas, A. R. AU - Beatty, G. L. AU - Albelda, S. M. AU - Levine, B. L. AU - Liu, X. PY - 2013 DA - 2013// TI - T cells expressing chimeric antigen receptors can cause anaphylaxis in humans JO - Cancer Immunol Res VL - 1 UR - https://doi.org/10.1158/2326-6066.CIR-13-0006 DO - 10.1158/2326-6066.CIR-13-0006 ID - Maus2013 ER - TY - JOUR AU - Diagnosis, C. M. PY - 2017 DA - 2017// TI - Management of anaphylaxis in precision medicine JO - J Allergy Clin Immunol VL - 140 UR - https://doi.org/10.1016/j.jaci.2017.06.012 DO - 10.1016/j.jaci.2017.06.012 ID - Diagnosis2017 ER - TY - JOUR AU - Matthys, P. AU - Dillen, C. AU - Proost, P. AU - Heremans, H. AU - Van Damme, J. AU - Billiau, A. PY - 1993 DA - 1993// TI - Modification of the anti-CD3-induced cytokine release syndrome by anti-interferon-gamma or anti-interleukin-6 antibody treatment: protective effects and biphasic changes in blood cytokine levels JO - Eur J Immunol VL - 23 UR - https://doi.org/10.1002/eji.1830230924 DO - 10.1002/eji.1830230924 ID - Matthys1993 ER - TY - STD TI - Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154-7.  ID - ref55 ER - TY - STD TI - Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.  ID - ref56 ER - TY - STD TI - Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959-70. ID - ref57 ER - TY - STD TI - van der Stegen SJC, Davies DM, Wilkie S, Foster J, Sosabowski JK, Burnet J, et al. Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity? J Immunol. 2013;191(9):4589-98.  ID - ref58 ER - TY - JOUR AU - Rose-John, S. PY - 2012 DA - 2012// TI - IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6 JO - Int J Biol Sci VL - 8 UR - https://doi.org/10.7150/ijbs.4989 DO - 10.7150/ijbs.4989 ID - Rose-John2012 ER - TY - JOUR AU - Hunter, C. A. AU - Jones, S. A. PY - 2015 DA - 2015// TI - IL-6 as a keystone cytokine in health and disease JO - Nat Immunol VL - 16 UR - https://doi.org/10.1038/ni.3153 DO - 10.1038/ni.3153 ID - Hunter2015 ER - TY - JOUR AU - Pathan, N. AU - Hemingway, C. A. AU - Alizadeh, A. A. AU - Stephens, A. C. AU - Boldrick, J. C. AU - Oragui, E. E. PY - 2004 DA - 2004// TI - Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock JO - Lancet VL - 363 UR - https://doi.org/10.1016/S0140-6736(03)15326-3 DO - 10.1016/S0140-6736(03)15326-3 ID - Pathan2004 ER - TY - STD TI - Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016; ID - ref62 ER - TY - STD TI - Obstfeld AE, Frey NV, Mansfield K, Lacey SF, June CH, Porter DL, et al. Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy; clinicopathological insights. Blood. 2017; ID - ref63 ER - TY - JOUR AU - Gust, J. AU - Hay, K. A. AU - Hanafi, L. -. A. AU - Li, D. AU - Myerson, D. AU - Gonzalez-Cuyar, L. F. PY - 2017 DA - 2017// TI - Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-17-0698 DO - 10.1158/2159-8290.CD-17-0698 ID - Gust2017 ER - TY - JOUR AU - Cifaldi, L. AU - Prencipe, G. AU - Caiello, I. AU - Bracaglia, C. AU - Locatelli, F. AU - De Benedetti, F. PY - 2015 DA - 2015// TI - Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome JO - Arthritis Rheumatol VL - 67 UR - https://doi.org/10.1002/art.39295 DO - 10.1002/art.39295 ID - Cifaldi2015 ER - TY - STD TI - Shimabukuro-Vornhagen A, Böll B, Kochanek M, Azoulay É, von Bergwelt-Baildon MS. Critical care of patients with cancer. CA Cancer J Clin. 2016; ID - ref66 ER - TY - JOUR AU - Fitzgerald, J. C. AU - Weiss, S. L. AU - Maude, S. L. AU - Barrett, D. M. AU - Lacey, S. F. AU - Melenhorst, J. J. PY - 2017 DA - 2017// TI - Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia JO - Crit Care Med VL - 45 UR - https://doi.org/10.1097/CCM.0000000000002053 DO - 10.1097/CCM.0000000000002053 ID - Fitzgerald2017 ER - TY - JOUR AU - Topp, M. S. AU - Gökbuget, N. AU - Stein, A. S. AU - Zugmaier, G. AU - O’Brien, S. AU - Bargou, R. C. PY - 2015 DA - 2015// TI - Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)71170-2 DO - 10.1016/S1470-2045(14)71170-2 ID - Topp2015 ER - TY - JOUR AU - Barrett, D. M. AU - Singh, N. AU - Hofmann, T. J. AU - Gershenson, Z. AU - Grupp, S. A. PY - 2016 DA - 2016// TI - Interleukin 6 is not made by chimeric antigen receptor T cells and does not impact their function JO - Blood VL - 128 ID - Barrett2016 ER - TY - JOUR AU - Singh, N. AU - Hofmann, T. J. AU - Gershenson, Z. AU - Levine, B. L. AU - Grupp, S. A. AU - Teachey, D. T. PY - 2017 DA - 2017// TI - Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function JO - Cytotherapy VL - 19 UR - https://doi.org/10.1016/j.jcyt.2017.04.001 DO - 10.1016/j.jcyt.2017.04.001 ID - Singh2017 ER - TY - JOUR AU - Bonifant, C. L. AU - Jackson, H. J. AU - Brentjens, R. J. AU - Curran, K. J. PY - 2016 DA - 2016// TI - Toxicity and management in CAR T-cell therapy JO - Mol Ther Oncolytics VL - 3 UR - https://doi.org/10.1038/mto.2016.11 DO - 10.1038/mto.2016.11 ID - Bonifant2016 ER - TY - STD TI - U.S. Food & drug administration. Press announcements - FDA approval brings first gene therapy to the United States. 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm. Accessed 18 Sep 2017. UR - https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm ID - ref72 ER - TY - JOUR AU - Chen, F. AU - Teachey, D. T. AU - Pequignot, E. AU - Frey, N. AU - Porter, D. AU - Maude, S. L. PY - 2016 DA - 2016// TI - Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy JO - J Immunol Methods VL - 434 UR - https://doi.org/10.1016/j.jim.2016.03.005 DO - 10.1016/j.jim.2016.03.005 ID - Chen2016 ER - TY - JOUR AU - Ruella, M. AU - Kenderian, S. S. AU - Shestova, O. AU - Klichinsky, M. AU - Melenhorst, J. J. AU - Wasik, M. A. PY - 2016 DA - 2016// TI - Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells (CART) for B cell neoplasms JO - Leukemia VL - 31 UR - https://doi.org/10.1038/leu.2016.262 DO - 10.1038/leu.2016.262 ID - Ruella2016 ER - TY - STD TI - Frimmel S, Schipper J, Henschel J, Tsui TY, Mitzner SR, Koball S. First description of SPAD combined with cytokine adsorption in fulminant liver failure and hemophagocytic syndrome due to generalized HSV-1 infection. Liver Transpl. 2014;20(12):1523-4. https://doi.org/10.1002/lt.24005. ID - ref75 ER - TY - JOUR AU - Greil, C. AU - Roether, F. AU - La Rosée, P. AU - Grimbacher, B. AU - Duerschmied, D. AU - Warnatz, K. PY - 2017 DA - 2017// TI - Rescue of Cytokine Storm due to HLH by Hemoadsorption in a CTLA4-deficient patient JO - J Clin Immunol VL - 37 UR - https://doi.org/10.1007/s10875-017-0377-7 DO - 10.1007/s10875-017-0377-7 ID - Greil2017 ER - TY - STD TI - Mei H, Jiang H, Wu Y, Guo T, Xia L, Jin R, et al. Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR-T therapy. Br J Haematol. 2017; ID - ref77 ER - TY - JOUR AU - Locke, F. L. AU - Neelapu, S. S. AU - Bartlett, N. L. AU - Siddiqi, T. AU - Chavez, J. C. AU - Hosing, C. M. PY - 2017 DA - 2017// TI - Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma JO - Mol Ther VL - 25 UR - https://doi.org/10.1016/j.ymthe.2016.10.020 DO - 10.1016/j.ymthe.2016.10.020 ID - Locke2017 ER - TY - JOUR AU - Ali, S. A. AU - Shi, V. AU - Maric, I. AU - Wang, M. AU - Stroncek, D. F. AU - Rose, J. J. PY - 2016 DA - 2016// TI - T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma JO - Blood VL - 128 UR - https://doi.org/10.1182/blood-2016-04-711903 DO - 10.1182/blood-2016-04-711903 ID - Ali2016 ER - TY - STD TI - Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322-31. ID - ref80 ER - TY - STD TI - Gauthier J, Turtle CJ. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med. 2018;66(2):50-2.  ID - ref81 ER - TY - STD TI - Marini BL, Sun Y, Burke PW, Perissinotti AJ. Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome. J Oncol Pharm Pract. 2016; 107815521667663 ID - ref82 ER - TY - JOUR AU - Grimaldi, C. AU - Finco, D. AU - Fort, M. M. AU - Gliddon, D. AU - Harper, K. AU - Helms, W. S. PY - 2016 DA - 2016// TI - Cytokine release: a workshop proceedings on the state-of-the-science, current challenges and future directions JO - Cytokine VL - 85 UR - https://doi.org/10.1016/j.cyto.2016.06.006 DO - 10.1016/j.cyto.2016.06.006 ID - Grimaldi2016 ER - TY - JOUR AU - Hartmann, J. AU - Schüßler-Lenz, M. AU - Bondanza, A. AU - Buchholz, C. J. PY - 2017 DA - 2017// TI - Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts JO - EMBO Mol Med VL - 9 UR - https://doi.org/10.15252/emmm.201607485 DO - 10.15252/emmm.201607485 ID - Hartmann2017 ER - TY - JOUR AU - Sadelain, M. AU - Rivière, I. AU - Riddell, S. PY - 2017 DA - 2017// TI - Therapeutic T cell engineering JO - Nature VL - 545 UR - https://doi.org/10.1038/nature22395 DO - 10.1038/nature22395 ID - Sadelain2017 ER - TY - JOUR AU - Fesnak, A. D. AU - June, C. H. AU - Levine, B. L. PY - 2016 DA - 2016// TI - Engineered T cells: the promise and challenges of cancer immunotherapy JO - Nat Rev Cancer VL - 16 UR - https://doi.org/10.1038/nrc.2016.97 DO - 10.1038/nrc.2016.97 ID - Fesnak2016 ER - TY - JOUR AU - Maude, S. L. AU - Laetsch, T. W. AU - Buechner, J. AU - Rives, S. AU - Boyer, M. AU - Bittencourt, H. PY - 2018 DA - 2018// TI - Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1709866 DO - 10.1056/NEJMoa1709866 ID - Maude2018 ER - TY - JOUR AU - Park, J. H. AU - Rivière, I. AU - Gonen, M. AU - Wang, X. AU - Sénéchal, B. AU - Curran, K. J. PY - 2018 DA - 2018// TI - Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1709919 DO - 10.1056/NEJMoa1709919 ID - Park2018 ER - TY - JOUR AU - Schuster, S. J. AU - Svoboda, J. AU - Chong, E. A. AU - Nasta, S. D. AU - Mato, A. R. AU - Anak, Ö. PY - 2017 DA - 2017// TI - Chimeric antigen receptor T cells in refractory B-cell lymphomas JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1708566 DO - 10.1056/NEJMoa1708566 ID - Schuster2017 ER - TY - JOUR AU - Garfall, A. L. AU - Maus, M. V. AU - Hwang, W. -. T. AU - Lacey, S. F. AU - Mahnke, Y. D. AU - Melenhorst, J. J. PY - 2015 DA - 2015// TI - Chimeric antigen receptor T cells against CD19 for multiple myeloma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504542 DO - 10.1056/NEJMoa1504542 ID - Garfall2015 ER - TY - JOUR AU - Von Stackelberg, A. AU - Locatelli, F. AU - Zugmaier, G. AU - Handgretinger, R. AU - Trippett, T. M. AU - Rizzari, C. PY - 2016 DA - 2016// TI - Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.67.3301 DO - 10.1200/JCO.2016.67.3301 ID - Von Stackelberg2016 ER - TY - JOUR AU - Topp, M. S. AU - Gökbuget, N. AU - Zugmaier, G. AU - Klappers, P. AU - Stelljes, M. AU - Neumann, S. PY - 2014 DA - 2014// TI - Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2014.56.3247 DO - 10.1200/JCO.2014.56.3247 ID - Topp2014 ER -